A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer

IntroductionFor unresectable stage III non-small cell lung cancer (NSCLC), the standard therapy consists of chemoradiotherapy (CRT) followed by durvalumab maintenance for responding patients. The present study reports on the safety and outcome of durvalumab use after CRT in a real-world, multicenter...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alessio Bruni, Vieri Scotti, Paolo Borghetti, Stefano Vagge, Salvatore Cozzi, Elisa D’Angelo, Niccolò Giaj Levra, Alessandra Fozza, Maria Taraborrelli, Gaia Piperno, Valentina Vanoni, Matteo Sepulcri, Marco Trovò, Valerio Nardone, Elisabetta Lattanzi, Said Bou Selman, Federica Bertolini, Davide Franceschini, Francesco Agustoni, Barbara Alicja Jereczek-Fossa, Stefano Maria Magrini, Lorenzo Livi, Frank Lohr, Andrea Riccardo Filippi
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	chemoradiotherapy immunotherapy stage III unresectable NSCLC Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/c19bbcb997264bcc8021500369c7f78b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer

Ejemplares similares